{
  "id": 17115559,
  "title": "Novo Has Big Plans for 2030. Should You Buy the Stock Now?",
  "url": "https://urgent.news/2026/10/29/novo-has-big-plans-for-2030-should-you-buy-the-stock-now",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-29T20:16:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/29/novo-has-big-plans-for-2030-should-you-buy-the-stock-now/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Novo (NVO) has experienced a substantial decline in its stock price over the past couple of years, losing more than 60% of its value. However, the company has set ambitious targets for 2030 that could potentially lead to improved financial results. This report examines whether Novo can achieve these goals and deliver competitive returns in the coming years.\n\nThe majority of Novo's revenue currently comes from GLP-1 products like Wegovy, Ozempic, and Rybelsus. Unfortunately, the company has lost market share to Eli Lilly (LLY) in this segment. To counteract this, Novo aims to regain ground in the market, while also diversifying its product lineup and pipeline.\n\nBy 2030, Novo intends to have more than five products generating over $5 billion in annual sales each. This goal is achievable as three of its current GLP-1 products generate billions in sales. However, Novo will need to introduce new products to meet its target, with some candidates showing promise.\n\nTwo notable candidates are CagriSema and zenagamtide. CagriSema, which mimics GLP-1 and amylin hormones, recently demonstrated favorable results in a Phase 3 trial against Wegovy. Meanwhile, zenagamtide, a next-generation diabetes and obesity product, is being tested in Phase 3 clinical trials with impressive early-stage results. Several additional candidates are expected to enter late-stage studies over the next few years.\n\nIn addition to these goals, Novo aims to have at least five Phase 3 diabetes and obesity programs in its pipeline and achieve five Phase 3 programs in other therapeutic areas by 2030. The company also targets to serve ten times as many obese patients with oral GLP-1 products, reaching over 60 million patients.\n\nInvestors should consider two main questions when evaluating Novo. Can the company actually achieve these goals, and if so, will its stock perform well over the next few years? Novo appears to be well-positioned to expand its product lineup and generate stronger revenue and earnings growth compared to its current performance. Licensing agreements, such as UBT251 and HRS-1596, indicate potential for future growth.\n\nWhile there are risks and uncertainties, Novo's pipeline depth provides multiple opportunities. The company is currently trading at approximately 12x forward earnings, significantly lower than the healthcare industry average of 19.2x. If Novo can maintain its revenue and earnings growth over the next few years, and as it replenishes its lineup and pipeline, its stock could deliver excellent returns from its current level.",
  "summary": "The company’s comeback strategy looks sound.",
  "key_points": [
    "Novo aims to have five products generating $5 billion in annual sales each by 2030.",
    "Novo is testing CagriSema and zenagamtide as potential new products in Phase 3 trials."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}